MedTrace Logo

Extracellular Matrix Marker of Arrhythmia Risk (EMMA)

NCT00376532 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 63

Last updated 2014-06-04

Study results available
· View outcomes & findings →

Summary

Assess whether serum levels of MMP 2 and or MMP 9 correlate with episodes of ventricular tachycardia or fibrillation in patients who have implantable cardioverter defibrillator devices.

Conditions

  • Myocardiopathies
  • Ischemia, Myocardial
  • Arrythmia
  • Death, Sudden, Cardiac

Sponsors & Collaborators

  • Medtronic

    collaborator INDUSTRY

  • Thomas Jefferson University

    lead OTHER

Principal Investigators

  • David J. Whellan, MD MHS FACC · Thomas Jefferson University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00376532 on ClinicalTrials.gov